The treatment of malignant tumors is a relatively perfect treatment model. With the continuous innovation of experimental and clinical research, the combination of multiple treatment methods and the clinical application of new drugs, the traditional treatment model, which used to be based on surgery, radiotherapy and chemotherapy as all treatment methods, has gradually improved and basically developed into a comprehensive treatment model with surgery, radiotherapy and molecular targeted therapy as the skeleton, supplemented by minimally invasive therapy, gene therapy and biological immunotherapy. In such a therapeutic model, it is often not possible to treat the patient with the same treatment. Under such a treatment model, the basis for guiding medical staff to develop further individualized treatment plans is often the results of clinical review, including radiological imaging, hematology, pathology, molecular biology, and endoscopy, etc. Therefore, we can say: regular review is a must for tumor treatment! In the long years of fighting with malignant tumor, regular review plays different roles in different stages and plays different roles. For patients with early stage of malignant tumors, who have undergone radical surgery and are clearly not in need of post-operative adjuvant therapy according to pathological type and immunohistochemistry, the role of regular review is like a set of monitoring equipment. As time goes by, the main indicators are monitored regularly to detect any trend of disease onset, and based on the “information” obtained, timely treatment is provided to nip the disease in the bud! After surgery, most patients need to undergo postoperative adjuvant radiotherapy and endocrine therapy to eliminate potential metastatic tumor cells. The methods of review at this time are basically hematological examination (mainly referring to tumor markers), taking post-operative imaging data as baseline data, and conducting imaging examination or other methods of examination in every two cycles of adjuvant chemotherapy or treatment cycles specified according to individual treatment modalities, to compare with the baseline data and clarify whether there is a trend of recurrence and determine further treatment plans accordingly. If the results of regular review after 6-8 cycles of adjuvant therapy generally show no signs of recurrence, then further adjuvant therapy can be stopped to avoid unnecessary physical and financial burdens caused by overtreatment. For patients with intermediate and advanced malignancies, the significance of periodic review during the treatment process is more obvious. A review after an appropriate treatment cycle can clarify the efficacy of the previous stage of treatment and evaluate the patient’s sensitivity to such treatments or drugs. If progression of disease (e.g., new metastases, progressive enlargement of the primary site, exponential increase in tumor markers, etc.) is detected after the previous phase of treatment, then a change in treatment regimen must follow. The endless chemotherapy paradigm has long been a palliative treatment option for intermediate and advanced malignancies. After several cycles of palliative treatment for different pathological types of malignancies, the disease is evaluated to be in a stable state, and then a period of respite can be performed. During this period, the patient’s quality of life will be substantially improved and enjoy a relatively comfortable living condition because they do not have to endure the pain caused by the treatment. The most important part of this period is the periodic review, which will tell you when you need to resume aggressive treatment to fight against the progression of malignancy in time. It will tell you when you need active treatment again to fight against malignant tumor development in time. Regular checkups bring us more than just monitoring the disease, sometimes it can bring us more help and even a surprise! Auntie Qu is a breast cancer patient who underwent radical surgery and post-operative adjuvant radiotherapy, but did not have the opportunity to undergo endocrine therapy because her immunohistochemistry showed that she had “triple negative” breast cancer. One year after the surgery, multiple pulmonary nodules were found, which were considered to be recurrent metastases, and Auntie Qu had to face the impending waves of chemotherapy. At this time, Auntie Qu underwent a puncture biopsy of the lung nodules and a recheck of immunohistochemistry on the advice of her doctor, which showed positive hormone receptors, and started regular endocrine therapy. Two months later, the review showed that the metastatic nodules in the lungs were less than before and the endocrine therapy was effective! Isn’t this the surprise of “a village in the dark”? What we mentioned above is the regular review of malignant tumor, maybe the word review in people’s mind only means tumor imaging, tumor markers and so on, in fact, it is much more than that! In the process of malignant tumor treatment, regular testing of blood routine, liver and kidney function and echocardiography are also extremely important. No matter radiotherapy or chemotherapy has more or less damaged the hematopoietic ability of bone marrow, blood routine review according to its action cycle can detect the potential danger in time and deal with it actively to avoid serious consequences. The drugs such as adriamycin and epi-amycin are cardiotoxic, and regular review of echocardiogram during the treatment can evaluate the heart function and the damage caused by the drugs in time, and adjust the treatment plan as soon as possible according to the specific situation to avoid unnecessary danger. All in all, regular review is a compulsory course for malignant tumor patients of any period and any stage of disease, and a compulsory course that gains much more than pays!